Many cancer patients receive chemotherapy at the end of life, even if their kind of cancer is known to be unresponsive to the drugs, according to a study reported at the recent annual meeting of the American Society of Clinical Oncologists held in San Francisco. "Many are concerned with the quality of end of life care and specifically that patients should not be overtreated with ineffective therapies that won't improve their quality of life," says Ezekiel Emanuel, chairman of the department of clinical bioethics at the US National Institutes of Health ( BMJ , No 7297).
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.